
Insomnia Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type
Description
Insomnia Therapeutics Market Summary
and Market Overview
Insomnia therapeutics, including benzodiazepines, nonbenzodiazepines, orexin antagonists, and melatonin antagonists, address a prevalent sleep disorder affecting 10-30% of the global population, with chronic insomnia at 5-10%. The market is driven by rising anxiety and depression, with a 25% increase in cases post-COVID-19, and high prevalence in women and the elderly (20-40%). Orexin antagonists like suvorexant and daridorexant, with low dependency, reduce sleep onset by 30 minutes and improve maintenance by 60%. The aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), health education, and 60% reimbursement coverage in OECD countries boost demand. The global insomnia therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 3%-7% through 2030.
Regional Market Trends
North America: The U.S. leads with high insomnia diagnoses and orexin antagonist adoption, while Canada focuses on sleep clinics.
Europe: Germany, France, and the UK drive growth with robust mental health services.
Asia Pacific: China and India see rising demand due to urban stress, with Japan emphasizing novel therapies.
Rest of the World: Brazil expands access to generics, while the Middle East addresses sleep health.
Application Analysis
Prescription: Expected growth of 3.5%-7.5%, driven by chronic insomnia. Trends focus on low-dependency drugs.
Over-the-Counter (OTC): Projected growth of 3.0%-7.0%, linked to mild cases. Advances emphasize natural supplements.
Type Analysis
Benzodiazepines: Expected growth of 2.5%-6.5%, used for short-term relief. Trends focus on limited use due to dependency.
Nonbenzodiazepines: Projected growth of 3.2%-7.2%, favored for safety. Advances emphasize short-acting agents.
Antidepressants: Anticipated growth of 2.8%-6.8%, suited for comorbid insomnia. Trends highlight low-dose options.
Orexin Antagonists: Expected growth of 4.0%-8.0%, valued for low dependency. Developments prioritize long-term efficacy.
Melatonin Antagonists: Expected growth of 3.5%-7.5%, used for sleep regulation. Trends focus on OTC formulations.
Others: Expected growth of 2.5%-6.5%, covering novel therapies. Trends highlight non-drug options.
Key Market Players
Merck: Offers suvorexant for insomnia.
Sanofi: Provides nonbenzodiazepine therapies.
Takeda Pharmaceutical: Develops sleep disorder treatments.
Pfizer: Supplies antidepressants for insomnia.
Idorsia: Specializes in daridorexant formulations.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D costs, but OTC supplements lower barriers.
Threat of Substitutes: High, with non-drug therapies like CBT-I competing, but drugs are primary for severe cases.
Bargaining Power of Buyers: High, as generics and OTC options increase price competition.
Bargaining Power of Suppliers: Low, with multiple API providers.
Competitive Rivalry: High, with players competing on efficacy and safety.
Market Opportunities and Challenges
Opportunities:
Addressing insomnia, affecting 10-30% of the population.
Leveraging orexin antagonists, improving sleep maintenance by 60%.
Managing anxiety and depression, with 25% case increase post-COVID-19.
Supporting an aging population, with 20-40% insomnia prevalence.
Utilizing 60% reimbursement coverage in OECD countries.
Expanding health education, increasing diagnosis rates to 50%.
Challenges:
High costs of novel therapies like orexin antagonists.
Regulatory scrutiny on dependency risks.
Competition from non-drug therapies like CBT-I.
Patient adherence issues with long-term treatments.
Limited access in low-income regions.
and Market Overview
Insomnia therapeutics, including benzodiazepines, nonbenzodiazepines, orexin antagonists, and melatonin antagonists, address a prevalent sleep disorder affecting 10-30% of the global population, with chronic insomnia at 5-10%. The market is driven by rising anxiety and depression, with a 25% increase in cases post-COVID-19, and high prevalence in women and the elderly (20-40%). Orexin antagonists like suvorexant and daridorexant, with low dependency, reduce sleep onset by 30 minutes and improve maintenance by 60%. The aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), health education, and 60% reimbursement coverage in OECD countries boost demand. The global insomnia therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 3%-7% through 2030.
Regional Market Trends
North America: The U.S. leads with high insomnia diagnoses and orexin antagonist adoption, while Canada focuses on sleep clinics.
Europe: Germany, France, and the UK drive growth with robust mental health services.
Asia Pacific: China and India see rising demand due to urban stress, with Japan emphasizing novel therapies.
Rest of the World: Brazil expands access to generics, while the Middle East addresses sleep health.
Application Analysis
Prescription: Expected growth of 3.5%-7.5%, driven by chronic insomnia. Trends focus on low-dependency drugs.
Over-the-Counter (OTC): Projected growth of 3.0%-7.0%, linked to mild cases. Advances emphasize natural supplements.
Type Analysis
Benzodiazepines: Expected growth of 2.5%-6.5%, used for short-term relief. Trends focus on limited use due to dependency.
Nonbenzodiazepines: Projected growth of 3.2%-7.2%, favored for safety. Advances emphasize short-acting agents.
Antidepressants: Anticipated growth of 2.8%-6.8%, suited for comorbid insomnia. Trends highlight low-dose options.
Orexin Antagonists: Expected growth of 4.0%-8.0%, valued for low dependency. Developments prioritize long-term efficacy.
Melatonin Antagonists: Expected growth of 3.5%-7.5%, used for sleep regulation. Trends focus on OTC formulations.
Others: Expected growth of 2.5%-6.5%, covering novel therapies. Trends highlight non-drug options.
Key Market Players
Merck: Offers suvorexant for insomnia.
Sanofi: Provides nonbenzodiazepine therapies.
Takeda Pharmaceutical: Develops sleep disorder treatments.
Pfizer: Supplies antidepressants for insomnia.
Idorsia: Specializes in daridorexant formulations.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D costs, but OTC supplements lower barriers.
Threat of Substitutes: High, with non-drug therapies like CBT-I competing, but drugs are primary for severe cases.
Bargaining Power of Buyers: High, as generics and OTC options increase price competition.
Bargaining Power of Suppliers: Low, with multiple API providers.
Competitive Rivalry: High, with players competing on efficacy and safety.
Market Opportunities and Challenges
Opportunities:
Addressing insomnia, affecting 10-30% of the population.
Leveraging orexin antagonists, improving sleep maintenance by 60%.
Managing anxiety and depression, with 25% case increase post-COVID-19.
Supporting an aging population, with 20-40% insomnia prevalence.
Utilizing 60% reimbursement coverage in OECD countries.
Expanding health education, increasing diagnosis rates to 50%.
Challenges:
High costs of novel therapies like orexin antagonists.
Regulatory scrutiny on dependency risks.
Competition from non-drug therapies like CBT-I.
Patient adherence issues with long-term treatments.
Limited access in low-income regions.
Table of Contents
92 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Insomnia Therapeutics Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Historical and Forecast Insomnia Therapeutics Market in North America (2020-2030)
- 8.1 Insomnia Therapeutics Market Size
- 8.2 Insomnia Therapeutics Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Insomnia Therapeutics Market Size by Type
- 8.5 Key Countries Analysis
- 8.5.1 United States
- 8.5.2 Canada
- 8.5.3 Mexico
- Chapter 9 Historical and Forecast Insomnia Therapeutics Market in South America (2020-2030)
- 9.1 Insomnia Therapeutics Market Size
- 9.2 Insomnia Therapeutics Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Insomnia Therapeutics Market Size by Type
- 9.5 Key Countries Analysis
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Chile
- 9.5.4 Peru
- Chapter 10 Historical and Forecast Insomnia Therapeutics Market in Asia & Pacific (2020-2030)
- 10.1 Insomnia Therapeutics Market Size
- 10.2 Insomnia Therapeutics Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Insomnia Therapeutics Market Size by Type
- 10.5 Key Countries Analysis
- 10.5.1 China
- 10.5.2 India
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 Southest Asia
- 10.5.6 Australia
- Chapter 11 Historical and Forecast Insomnia Therapeutics Market in Europe (2020-2030)
- 11.1 Insomnia Therapeutics Market Size
- 11.2 Insomnia Therapeutics Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Insomnia Therapeutics Market Size by Type
- 11.5 Key Countries Analysis
- 11.5.1 Germany
- 11.5.2 France
- 11.5.3 United Kingdom
- 11.5.4 Italy
- 11.5.5 Spain
- 11.5.6 Belgium
- 11.5.7 Netherlands
- 11.5.8 Austria
- 11.5.9 Poland
- 11.5.10 Russia
- Chapter 12 Historical and Forecast Insomnia Therapeutics Market in MEA (2020-2030)
- 12.1 Insomnia Therapeutics Market Size
- 12.2 Insomnia Therapeutics Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Insomnia Therapeutics Market Size by Type
- 12.5 Key Countries Analysis
- 12.5.1 Egypt
- 12.5.2 Israel
- 12.5.3 South Africa
- 12.5.4 Gulf Cooperation Council Countries
- 12.5.5 Turkey
- Chapter 13 Summary For Global Insomnia Therapeutics Market (2020-2025)
- 13.1 Insomnia Therapeutics Market Size
- 13.2 Insomnia Therapeutics Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Insomnia Therapeutics Market Size by Type
- Chapter 14 Global Insomnia Therapeutics Market Forecast (2025-2030)
- 14.1 Insomnia Therapeutics Market Size Forecast
- 14.2 Insomnia Therapeutics Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Insomnia Therapeutics Type Forecast
- Chapter 15 Analysis of Global Key Vendors
- 15.1 Merck
- 15.1.1 Company Profile
- 15.1.2 Main Business and Insomnia Therapeutics Information
- 15.1.3 SWOT Analysis of Merck
- 15.1.4 Merck Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Sanofi
- 15.2.1 Company Profile
- 15.2.2 Main Business and Insomnia Therapeutics Information
- 15.2.3 SWOT Analysis of Sanofi
- 15.2.4 Sanofi Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Takeda Pharmaceutical
- 15.3.1 Company Profile
- 15.3.2 Main Business and Insomnia Therapeutics Information
- 15.3.3 SWOT Analysis of Takeda Pharmaceutical
- 15.3.4 Takeda Pharmaceutical Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Pfizer
- 15.4.1 Company Profile
- 15.4.2 Main Business and Insomnia Therapeutics Information
- 15.4.3 SWOT Analysis of Pfizer
- 15.4.4 Pfizer Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Vanda Pharmaceuticals
- 15.5.1 Company Profile
- 15.5.2 Main Business and Insomnia Therapeutics Information
- 15.5.3 SWOT Analysis of Vanda Pharmaceuticals
- 15.5.4 Vanda Pharmaceuticals Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.6 Teva Pharmaceutical
- 15.6.1 Company Profile
- 15.6.2 Main Business and Insomnia Therapeutics Information
- 15.6.3 SWOT Analysis of Teva Pharmaceutical
- 15.6.4 Teva Pharmaceutical Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.7 Viatris
- 15.7.1 Company Profile
- 15.7.2 Main Business and Insomnia Therapeutics Information
- 15.7.3 SWOT Analysis of Viatris
- 15.7.4 Viatris Insomnia Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms
- Table Research Scope of Insomnia Therapeutics Report
- Table Data Sources of Insomnia Therapeutics Report
- Table Major Assumptions of Insomnia Therapeutics Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Insomnia Therapeutics Picture
- Table Insomnia Therapeutics Classification
- Table Insomnia Therapeutics Applications
- Table Drivers of Insomnia Therapeutics Market
- Table Restraints of Insomnia Therapeutics Market
- Table Opportunities of Insomnia Therapeutics Market
- Table Threats of Insomnia Therapeutics Market
- Table Covid-19 Impact For Insomnia Therapeutics Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Insomnia Therapeutics
- Table Cost Structure Analysis of Insomnia Therapeutics
- Table Key End Users
- Table Latest News of Insomnia Therapeutics Market
- Table Merger and Acquisition
- Table Planned/Future Project of Insomnia Therapeutics Market
- Table Policy of Insomnia Therapeutics Market
- Table 2020-2030 North America Insomnia Therapeutics Market Size
- Figure 2020-2030 North America Insomnia Therapeutics Market Size and CAGR
- Table 2020-2030 North America Insomnia Therapeutics Market Size by Application
- Table 2020-2025 North America Insomnia Therapeutics Key Players Revenue
- Table 2020-2025 North America Insomnia Therapeutics Key Players Market Share
- Table 2020-2030 North America Insomnia Therapeutics Market Size by Type
- Table 2020-2030 United States Insomnia Therapeutics Market Size
- Table 2020-2030 Canada Insomnia Therapeutics Market Size
- Table 2020-2030 Mexico Insomnia Therapeutics Market Size
- Table 2020-2030 South America Insomnia Therapeutics Market Size
- Figure 2020-2030 South America Insomnia Therapeutics Market Size and CAGR
- Table 2020-2030 South America Insomnia Therapeutics Market Size by Application
- Table 2020-2025 South America Insomnia Therapeutics Key Players Revenue
- Table 2020-2025 South America Insomnia Therapeutics Key Players Market Share
- Table 2020-2030 South America Insomnia Therapeutics Market Size by Type
- Table 2020-2030 Brazil Insomnia Therapeutics Market Size
- Table 2020-2030 Argentina Insomnia Therapeutics Market Size
- Table 2020-2030 Chile Insomnia Therapeutics Market Size
- Table 2020-2030 Peru Insomnia Therapeutics Market Size
- Table 2020-2030 Asia & Pacific Insomnia Therapeutics Market Size
- Figure 2020-2030 Asia & Pacific Insomnia Therapeutics Market Size and CAGR
- Table 2020-2030 Asia & Pacific Insomnia Therapeutics Market Size by Application
- Table 2020-2025 Asia & Pacific Insomnia Therapeutics Key Players Revenue
- Table 2020-2025 Asia & Pacific Insomnia Therapeutics Key Players Market Share
- Table 2020-2030 Asia & Pacific Insomnia Therapeutics Market Size by Type
- Table 2020-2030 China Insomnia Therapeutics Market Size
- Table 2020-2030 India Insomnia Therapeutics Market Size
- Table 2020-2030 Japan Insomnia Therapeutics Market Size
- Table 2020-2030 South Korea Insomnia Therapeutics Market Size
- Table 2020-2030 Southeast Asia Insomnia Therapeutics Market Size
- Table 2020-2030 Australia Insomnia Therapeutics Market Size
- Table 2020-2030 Europe Insomnia Therapeutics Market Size
- Figure 2020-2030 Europe Insomnia Therapeutics Market Size and CAGR
- Table 2020-2030 Europe Insomnia Therapeutics Market Size by Application
- Table 2020-2025 Europe Insomnia Therapeutics Key Players Revenue
- Table 2020-2025 Europe Insomnia Therapeutics Key Players Market Share
- Table 2020-2030 Europe Insomnia Therapeutics Market Size by Type
- Table 2020-2030 Germany Insomnia Therapeutics Market Size
- Table 2020-2030 France Insomnia Therapeutics Market Size
- Table 2020-2030 United Kingdom Insomnia Therapeutics Market Size
- Table 2020-2030 Italy Insomnia Therapeutics Market Size
- Table 2020-2030 Spain Insomnia Therapeutics Market Size
- Table 2020-2030 Belgium Insomnia Therapeutics Market Size
- Table 2020-2030 Netherlands Insomnia Therapeutics Market Size
- Table 2020-2030 Austria Insomnia Therapeutics Market Size
- Table 2020-2030 Poland Insomnia Therapeutics Market Size
- Table 2020-2030 Russia Insomnia Therapeutics Market Size
- Table 2020-2030 MEA Insomnia Therapeutics Market Size
- Figure 2020-2030 MEA Insomnia Therapeutics Market Size and CAGR
- Table 2020-2030 MEA Insomnia Therapeutics Market Size by Application
- Table 2020-2025 MEA Insomnia Therapeutics Key Players Revenue
- Table 2020-2025 MEA Insomnia Therapeutics Key Players Market Share
- Table 2020-2030 MEA Insomnia Therapeutics Market Size by Type
- Table 2020-2030 Egypt Insomnia Therapeutics Market Size
- Table 2020-2030 Israel Insomnia Therapeutics Market Size
- Table 2020-2030 South Africa Insomnia Therapeutics Market Size
- Table 2020-2030 Gulf Cooperation Council Countries Insomnia Therapeutics Market Size
- Table 2020-2030 Turkey Insomnia Therapeutics Market Size
- Table 2020-2025 Global Insomnia Therapeutics Market Size by Region
- Table 2020-2025 Global Insomnia Therapeutics Market Size Share by Region
- Table 2020-2025 Global Insomnia Therapeutics Market Size by Application
- Table 2020-2025 Global Insomnia Therapeutics Market Share by Application
- Table 2020-2025 Global Insomnia Therapeutics Key Vendors Revenue
- Figure 2020-2025 Global Insomnia Therapeutics Market Size and Growth Rate
- Table 2020-2025 Global Insomnia Therapeutics Key Vendors Market Share
- Table 2020-2025 Global Insomnia Therapeutics Market Size by Type
- Table 2020-2025 Global Insomnia Therapeutics Market Share by Type
- Table 2025-2030 Global Insomnia Therapeutics Market Size by Region
- Table 2025-2030 Global Insomnia Therapeutics Market Size Share by Region
- Table 2025-2030 Global Insomnia Therapeutics Market Size by Application
- Table 2025-2030 Global Insomnia Therapeutics Market Share by Application
- Table 2025-2030 Global Insomnia Therapeutics Key Vendors Revenue
- Figure 2025-2030 Global Insomnia Therapeutics Market Size and Growth Rate
- Table 2025-2030 Global Insomnia Therapeutics Key Vendors Market Share
- Table 2025-2030 Global Insomnia Therapeutics Market Size by Type
- Table 2025-2030 Insomnia Therapeutics Global Market Share by Type
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.